缬沙坦胶囊对原发性高血压的降压疗效及预后观察

Antihypertensive efficacy and prognosis of valsartan capsules in essential hypertension

目的探讨缬沙坦胶囊(商品名:代文)对原发性高血压患者的血压控制效果,并分析患者预后情况。方法300例原发性高血压患者,均口服缬沙坦胶囊治疗,部分血压未得到理想控制患者加服双氢克尿噻片。观察患者血压控制情况,对比患者用药前后坐位及立位血压、心率、24 h尿蛋白定量、血肌酐、尿素氮水平,不良反应发生情况。结果300例患者中,完成8周观察298例,2例患者治疗中出现过敏性皮炎退出研究。153例患者仅服用缬沙坦胶囊治疗即可有效控制血压,占比51.34%;缬沙坦+12.5 mg双氢克尿噻片治疗有效控制血压232例,占比77.85%;缬沙坦+25 mg双氢克尿噻片治疗有效控制血压261例,占比87.58%。治疗后,患者坐位舒张压(82.45±5.98)mm Hg(1 mm Hg=0.133 kPa)、收缩压(133.98±9.17)mm Hg及立位舒张压(81.32±6.04)mm Hg、收缩压(133.68±9.35)mm Hg均低于治疗前的(96.17±3.62)、(155.50±10.53)、(94.52±4.72)、(155.12±11.02)mm Hg,差异有统计学意义(P<0.05)。患者治疗前的坐位心率为(74.56±7.56)次/min,与治疗后的(74.23±6.85)次/min对比,差异无统计学意义(P>0.05)。患者治疗后24 h尿蛋白定量、血肌酐及尿素氮水平与治疗前对比,差异无统计学意义(P>0.05)。无患者发生严重不良反应,不良反应总发生率为3.36%(10/298)。结论缬沙坦胶囊可有效控制原发性高血压患者的坐位、立位的收缩压、舒张压,患者治疗中无严重不良反应发生,不良反应总发生率低,对心率、实验室指标无影响,具备临床推广应用价值。

Objective To investigate the effect of valsartan capsule(trade name:Diovan)on blood pressure control in patients with essential hypertension,and analyze the prognosis of patients.Methods All 300 patients with essential hypertension were treated with oral valsartan capsules,and some patients whose blood pressure was not well controlled were given additional hydrochlorothiazide tablets.The control of blood pressure was observed,and the blood pressure in sitting and standing position,heart rate,24-h urinary protein quantity,blood creatinine and urea nitrogen levels,and the occurrence of adverse reactions were compared before and after drug administration.Results Of the 300 patients,298 cases completed 8 weeks of observation and 2 cases developed allergic dermatitis during treatment and withdrew from the study.The blood pressure of 153 patients was effectively controlled by taking only valsartan capsules,accounting for 51.34%;232 patients treated with valsartan and 12.5 mg hydrochlorothiazide tablets,accounting for 77.85%;261 patients treated with valsartan and 25 mg hydrochlorothiazide tablets,accounting for 87.58%.After treatment,the sitting diastolic blood pressure(82.45±5.98)mm Hg(1 mm Hg=0.133 kPa),sitting systolic blood pressure(133.98±9.17)mm Hg,and standing diastolic blood pressure(81.32±6.04)mm Hg,standing systolic blood pressure(133.68±9.35)mm Hg were all lower than(96.17±3.62),(155.5±10.53),(94.52±4.72),(155.12±11.02)mm Hg before treatment,and the differences were statistically significant(P<0.05).The sitting heart rate was(74.56±7.56)beats/min before treatment,which was not statistically significant compared with(74.23±6.85)beats/min after treatment(P>0.05).There was no statistically significant difference in the 24-h urinary protein quantity,blood creatinine and urea nitrogen levels of patients after treatment compared with those before treatment(P>0.05).No patients had serious adverse reactions,and the total incidence of adverse reactions was 3.36%(10/298).Conclusion Valsartan capsule can effectively control the systolic blood pressure and diastolic blood pressure in sitting and standing positions of patients with essential hypertension.No serious adverse events occur during the treatment of the patients,the total incidence of adverse events is low,and it has no effect on heart rate and laboratory indicators,which contains clinical promotion and application value.